Prellis: Prellis Biologics Raises $35M in Series C Funding

Prellis Biologics, a San Francisco, CA-based biotherapeutics company, raised $35M in Series C funding. The round, which brings funding to date to $64.5m, was led by Celesta Capital and Avidity Partners with participation from Khosla Ventures, SOSV, True Ventures, and Lucas Venture Group. The company intends to use the funds to expand its proprietary, first-in-class human immune system-based drug discovery [...]The post Prellis Biologics Raises $35M in Series C Funding appeared first on FinSMEs.